Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Showing 20 of 28375 trials
Groceries for Residents of Southeastern USA to Stop Hypertension
NCT06891911
Recruiting
Conditions Hypertension, Elevated Blood Pressure, C...
Phase NA
Enrollment 150
Locations 1 sites
Compensation stipend available
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • Dietitian-Assisted DASH groceries
  • Self-directed shopping

Primary Outcomes

  • Self-measured systolic blood pressure
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-14
Completion: 2026-06
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beth Israel Deaconess Medical Center
Collaborators: American Heart Association, University of Vermont
Contact Information
Study Contact:
Stephen P. Juraschek, MD, PhD
6177541416
sjurasch@bidmc.harvard.edu
Interventions
  • Dietitian-Assisted DASH groceries
  • Self-directed shopping
Study Locations (1 sites)
Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215 United States
Eligibility Criteria
Inclusion Criteria: 1. Resting systolic blood pressure of 120 to \<160 mm Hg and diastolic blood pressure \<110 mm Hg 2. Resident of Florida, Georgia, and Tennessee 3. Able to receive home-delivered groceries or pick them up at a convenient location and willing to eat only the groceries provided over a 4-week period 4. Have access to refrigeration, cooking appliances, and Wi-Fi/cellular service 5. Have access to mobile device or computer to be able to conduct grocery orders via video conference and send/receive text messages 6. Willing and able to complete required measurement procedures 7. Able to provide consent for the study 8. Has access to a primary care team, urgent care center, or emergency room the study team can refer to for follow up care if warranted during the study Exclusion Criteria: A. Laboratory Exclusions: 1. Serum potassium ≥5.0 mmol/L or \<3.5 mmol/L 2. Estimated glomerular filtration rate (eGFR) \<30 mL/min per 1.73 m\^2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation 3. Hemoglobin A1c ≥6.5% B. Medication Exclusions: Unstable doses (i.e. a change in the 6 months prior to screening or randomization or planning to start within study period) of the following: 1. GLP-1 and dual GLP-1/GIP receptor agonists 2. Anti-hypertension medications 3. Sodium-glucose co-transporter 2 (SGLT2) inhibitors 4. Glucose lowering medications Use of any of the following medications: 1. Potassium supplement, except if part of a multivitamin 2. Warfarin (Coumadin) 3. Chronic oral corticosteroid (intermittent use is okay) 4. Weight loss medications (non-GLP-1 receptor agonists) 5. Sulfonylurea or any insulin use Any medication not compatible with participation as determined by the investigators C. Physical Exclusions: 1. Systolic blood pressure: \<120 or ≥160 mm Hg or diastolic blood pressure ≥110 mm Hg 2. Arm circumference \>52 cm (or the upper limit of the validated BP device) D. Medical History Exclusions: 1. Self-reported weight loss or gain of 15 pounds during prior 2 months 2. Active cardiovascular disease or any event in the prior 6 months, including coronary artery bypass grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), myocardial infarction (MI), cerebrovascular accident (CVA), or congestive heart failure (CHF) exacerbation requiring hospital admission 3. Cancer diagnosis or treatment in the last 2 years (non-melanoma skin cancer or localized breast or prostate or bladder cancer not requiring systemic therapy is acceptable) 4. Gastrointestinal surgery or history that affects nutrition absorption or requires a specific diet that will deter DASH diet adherence 5. Pregnancy or lactation or planned pregnancy during the study period 6. Any emergency department (ED) visit for asthma or chronic obstructive pulmonary disease (COPD) in the last 6 months 7. Hypoglycemia hospitalization in the last 12 months 8. Any other serious illness or condition not compatible with participation as determined by the investigators E. Lifestyle and Other Exclusions: 1. Significant food allergies, preferences, intolerances, or dietary requirements that would interfere with diet adherence 2. Consumption of more than 14 alcoholic drinks per week or consumption of more than 6 drinks on one or more occasion per week 3. Active substance use disorder that would interfere with participation 4. Extreme food insecurity 5. Participation in or planning to start weight loss program 6. Current participation in another clinical trial that could interfere with the study protocol 7. Anticipated change in residence outside of eligible states prior to the end of the study 8. Families with more than 6 adults at dinner time (children count as half an adult) F. Investigator discretion
Comparison of Once-Weekly Trelagliptin vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes
NCT06913101
Active, positions filled
Conditions Type 2 Diabetes Mellitus (T2DM)
Phase NA
Enrollment 102
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • Trelagliptin 100 mg
  • Vildagliptin 50 mg

Primary Outcomes

  • Percentage of Participants Achieving HbA1c <7%
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Active, positions filled
Start Date: 2024-11-15
Completion: 2025-05-15
Eligibility
Age: 30 Years
Sex: ALL
Volunteers: false
Enrollment: 102 (ACTUAL)
Sponsor & Investigators
Lead Sponsor: PNS Hafeez - Naval Hospital
Principal Investigators:
  • Hamza Ali (PRINCIPAL_INVESTIGATOR) - PNS Hafeez - Naval Hospital
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Trelagliptin 100 mg
  • Vildagliptin 50 mg
Study Locations (1 sites)
PNS Hafeez - Naval Hospital, Islamabad, Federal Territory 44000 Pakistan
Eligibility Criteria
Inclusion Criteria: * Adults aged 30-60 years. * Both male and female. * Diagnosed with type 2 diabetes mellitus. * HbA1c levels between 7.5% and 9.5% at screening. * Able to provide informed consent. Exclusion Criteria: * Type 1 diabetes mellitus or a history of ketoacidosis. * Use of insulin or any antidiabetic drugs other than metformin within 3 months prior to the start of the study. * Significant cardiovascular disease, including recent myocardial infarction (within the last 6 months), unstable angina, or uncontrolled hypertension. * Chronic kidney disease (stage 3 or worse) or hepatic or pancreatic dysfunction. * Pregnant or breastfeeding or planning to become pregnant during the study duration. * Participation in another clinical trial within 30 days prior to enrollment. * Known hypersensitivity to trelagliptin, vildagliptin, or any components of their formulations. * Any medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study. * Participants for whom blood sugar control by insulin preparations is desired (for example, participants with severe ketosis, diabetic coma or precoma, type 1 diabetes mellitus, severe infection, or serious trauma before or after surgery). * Participants with unstable proliferative diabetic retinopathy.
Multimodal Monitoring Study in Neuro Critical Care
NCT06900101
Recruiting
Conditions Subarachnoidal Hemorrhage, Intacranial H...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • Study the evolution and correlation between cerebral autoregulation index

Primary Outcomes

  • Correlation between ORx and PRx
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-01-01
Completion: 2030-12-01
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospices Civils de Lyon
Contact Information
Study Contact:
Dr Baptiste Balança
04 72 35 75 76
baptiste.balanca@chu-lyon.fr
Interventions
  • Study the evolution and correlation between cerebral autoregulation index
Study Locations (1 sites)
Hopital Pierre Wertheimer, France, Bron 69500 France
Eligibility Criteria
Inclusion Criteria: * \- Patients hospitalized in neurologic critical care in Wertheimer Hospital, Bron * Monitored with the CNS MOBERG® monitoring system Exclusion Criteria: * \- Refusal to participate * Patients under legal protection
Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer
NCT06916637
Recruiting
Conditions Breast Cancer, Breast Cancer, HER2-Expre...
Phase Not Applicable
Enrollment 40
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • 18F-HER2 Affibody PET scan

Primary Outcomes

  • SUV
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-04-09
Completion: 2027-12
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Affiliated Hospital of Qingdao University
Contact Information
Study Contact:
Zhenguang Wang, Doctoral Degree
+86-0532-82913318
wangzhenguang@qdu.edu.cn
Interventions
  • 18F-HER2 Affibody PET scan
Study Locations (1 sites)
Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000 China
Eligibility Criteria
Inclusion Criteria: * Age 18-75 years, ECOG score 0 or 1. * Clinically or pathologically confirmed diagnosis of patients with HER2 expression breast cancer or suspected expression breast cancer. * Life expectancy ≥ 12 weeks. * At least one measurable target lesion according to RECIST 1.1 criteria. * All participants of reproductive potential (regardless of gender) must commit to using effective contraceptive methods throughout the trial participation and for 6 months after the last PET scan. * Ability to understand and voluntarily sign the informed consent form, with good compliance. Exclusion Criteria: * Severe hepatic or renal dysfunction. * Pregnant or lactating women, or women planning to become pregnant. * Inability to lie supine for half an hour. * Refusal to participate in this clinical study. * Suffering from claustrophobia or other mental illnesses. * Other conditions that the investigator deems unsuitable for participation in the trial.
Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
NCT06900647
Recruiting
Conditions Metastatic Breast Cancer, Recurrent Brea...
Phase PHASE1
Enrollment 20
Locations 1 sites
Compensation Phase 1: Typically $1,000-$5,000
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • Bortezomib (B)
  • Cisplatin (CDDP)
  • Bortezomib (B)
  • Bortezomib (B)
  • Cisplatin (CDDP)

Primary Outcomes

  • Dose-limiting toxicities (DLTs)
  • Maximum Tolerated Dose (MTD)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-01-01
Completion: 2028-06-30
Eligibility
Age: 18 Years
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-sen University
Principal Investigators:
  • Yan-xia Shi, Doctor (PRINCIPAL_INVESTIGATOR) - Sun Yat-sen University
Contact Information
Study Contact:
Yanxia Shi, Doctor
86-020-87343486
shiyx@sysucc.org.cn
Interventions
  • Bortezomib (B)
  • Cisplatin (CDDP)
  • Bortezomib (B)
  • Bortezomib (B)
  • Cisplatin (CDDP)
Study Locations (1 sites)
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510000 China
Eligibility Criteria
Inclusion Criteria: 1. Women aged 18 years and above with pathologically confirmed recurrent or metastatic advanced breast cancer ; 2. The patient has tumor specimens (formalin-fixed, paraffin-embedded or fresh pre-treated recurrent tumor tissue); 3. Patients who have failed standard treatment in the late stage; 4. At least one measurable lesion; 5. ECOG PS : 0-2 points; 6. Estimated survival period ≥12 weeks; 7. The function level of major organs meets the following standards: 1\) The blood routine examination standards must meet: ANC ≥1.5×109/L, PLT ≥75×109/L, Hb ≥85g/L (no blood transfusion and blood products within 14 days, no use of G-CSF and other hematopoietic stimulating factors for correction) 2) Biochemical examinations must meet the following standards: TBIL \<1.5×ULN, ALT, AST \<2.5×ULN, ALT, AST \<5×ULN for patients with liver metastasis, BUN and Cr ≤1×ULN or endogenous creatinine clearance ≥50ml/min (Cockcroft-Gault formula); 8. Women of childbearing age must have taken reliable contraceptive measures, or have undergone a pregnancy test (serum or urine) within 7 days before enrollment, with a negative result, and are willing to use appropriate contraceptive methods during the trial and 8 weeks after the last administration of the trial drug. 9\. The subjects voluntarily join this study, have good compliance, and cooperate with follow-up. Exclusion Criteria: Any of the following will be considered as meeting the exclusion criteria of the study: 1. Patients with acute active hepatitis B or acute active hepatitis C; 2. Any serious underlying disease, comorbidity and active infection 3. Currently receiving other anti-tumor treatments; 4. History of epilepsy or epileptic-induced condition; 5. Patients who are pregnant or breastfeeding; 6. Those with poor compliance or unable to undergo normal follow-up; 7. Allergic to study drugs; 8. Patients diagnosed with other malignant tumors within 5 years, except for the following: surgically resected non-melanoma skin cancer, adequately treated cervical carcinoma in situ, surgically radically treated ductal carcinoma in situ, or malignant tumors diagnosed 2 years ago with no current evidence of disease and untreated ≤ 2 years before randomization; 9. The researcher determines other situations that may affect the conduct of the clinical study and the determination of the study results.
Towards Digital Management of Paediatric Asthma
NCT06902766
Recruiting
Conditions Pediatric Asthma
Phase NA
Enrollment 50
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • Active telemonitoring using real-time data from digital inhalers.
  • Standard

Primary Outcomes

  • Change in asthma severity measured by the Composite Asthma Severity Index (CASI)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-25
Completion: 2027-01
Eligibility
Age: 4 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Collaborators: URC-CIC Paris Descartes Necker Cochin
Principal Investigators:
  • David DUMMOND, MD, PhD (PRINCIPAL_INVESTIGATOR) - Hôpital Necker Enfants Malades AP-HP
Contact Information
Study Contact:
David DUMMOND, MD, PhD
01 87 89 20 28
david.drummond@aphp.fr
sarah BOUCHARD, Project manager
01 42 19 28 79
sarah.bouchard@ahp.fr
Interventions
  • Active telemonitoring using real-time data from digital inhalers.
  • Standard
Study Locations (1 sites)
Hôpital Necker Enfants Malades AP-HP, Paris, 75015 France
Eligibility Criteria
Inclusion Criteria: * Aged 4 to 12, whose asthma has been diagnosed by a physician * Followed up for their asthma by a pediatrician or pediatric pulmonologist * With asthma severity corresponding to GINA grades 2, 3 or 4 (Global Asthma Initiative Guidelines) * Whose controller and reliever treatments are administered using pressurized metered-dose inhalers (p-MDIs) * With social security * Whose parents or legal guardian(s): * Have given their written and informed consent for their child's participation and their participation, * Have a smartphone in the household that can download the application and is compatible with it, * Are capable, in the opinion of the investigator, of understanding the use of the mobile application and module FRENCH CARE specifically dedicated to the research and the digital inhalers provided. Non-inclusion Criteria: * Patients with another pathology that could interfere with the evaluation of the endpoints (e.g, bronchopulmonary dysplasia, cystic fibrosis, etc.) * Patients whose parents or legal representative(s) are, in the opinion of the investigator, unable to understand the purpose of the study and/or express their consent. * Patients benefiting from State Medical Aid Exclusion Criteria: \- Patient who did not use the system within 15 days of the inclusion visit
Adaptation and Examination of a Trauma-informed Intervention for Pregnant Veterans
NCT06906185
Recruiting
Conditions Trauma-related Mental Health Symptoms
Phase NA
Enrollment 36
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • Calm Moms-V
  • Care As Usual

Primary Outcomes

  • Acceptability of Intervention Measure (AIM)
  • Feasibility of Intervention Measure (FIM)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-30
Completion: 2030-03-29
Eligibility
Age: No restriction
Sex: FEMALE
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: VA Office of Research and Development
Principal Investigators:
  • Mary E Shapiro, PhD MS (PRINCIPAL_INVESTIGATOR) - Southeast Louisiana Veterans Health Care System, New Orleans, LA
Contact Information
Study Contact:
Mary E Shapiro, PhD MS
(504) 507-2000
mary.shapiro1@va.gov
Interventions
  • Calm Moms-V
  • Care As Usual
Study Locations (1 sites)
Southeast Louisiana Veterans Health Care System, New Orleans, LA, New Orleans, Louisiana 70119 United States
Eligibility Criteria
Inclusion Criteria: * Pregnant (any trimester) * Endorse a DSM-5-TR Criterion A traumatic event as indexed by the trauma exposure portion of the PTSD screen for primary care (PC-PTSD-5) * Endorse clinically elevated anxiety (as indexed by a total score of \> 3 on the GAD-2) or depression symptoms (as indexed by a total score of \> 3 on the PHQ-2) * Able to participate in an online intervention (i.e., have internet and smartphone, tablet, or computer access) Of note, pregnant Veterans will still be eligible if they are in concurrent psychotherapy and/or using psychotropic medications. Exclusion Criteria: * Evidence of a significant mental illness that would impede completion of the intervention * (i.e., active psychosis, uncontrolled bipolar disorder, a severe alcohol/substance use disorder, or suicidal ideation or behavior that requires immediate hospitalization or treatment) Evidence of a significant mental illness will be determined via pre-enrollment chart review.
Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients
NCT06892093
Recruiting
Conditions HER2-positive Breast Cancer, Diarrhea Ca...
Phase NA
Enrollment 308
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • Probiotics
  • Placebo
  • Loperamide

Primary Outcomes

  • Incidence of Grade ≥3 Diarrhea
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-07
Completion: 2027-12
Eligibility
Age: 18 Years
Sex: FEMALE
Volunteers: false
Enrollment: 308 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators: Jiangnan University
Contact Information
Study Contact:
Jianli Zhao
+86 15920589334
zhaojianli1988@126.com
Interventions
  • Probiotics
  • Placebo
  • Loperamide
Study Locations (1 sites)
Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong China
Eligibility Criteria
Inclusion Criteria Participants must meet all of the following criteria: 1. Female patients aged ≥18 years, diagnosed with HER2-positive breast cancer. 2. Scheduled to receive Neratinib therapy (monotherapy or in combination), based on clinical guidelines. 3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, with an expected survival of at least 3 months. 4. Left ventricular ejection fraction (LVEF) ≥ 50%. 5. Resolution of any prior treatment-related toxicity to Grade ≤1 (per CTCAE v5.0), with AST and ALT ≤ 2.5 × the upper limit of normal (ULN), and total bilirubin ≤ 1.5 × ULN. 6. Adequate bone marrow function, defined as: White blood cell count ≥ 3.0 × 10⁹/L Neutrophil count ≥ 1.5 × 10⁹/L Platelet count ≥ 100 × 10⁹/L Hemoglobin ≥ 90 g/L Serum creatinine ≤ 1.5 × ULN 7. No persistent gastrointestinal symptoms, such as hematochezia, chronic constipation, or abdominal pain. 8. No evidence of structural gastrointestinal abnormalities confirmed by gastroscopy or other relevant examinations. Exclusion Criteria Participants will be excluded if they meet any of the following criteria: 1. Conditions that significantly impair swallowing, digestion, or gastrointestinal drug absorption. 2. History of chronic gastrointestinal diseases, including but not limited to inflammatory bowel disease (IBD), gastrointestinal tumors, or malabsorption syndromes. 3. Severe cardiovascular diseases that may interfere with study treatment, including but not limited to: Life-threatening arrhythmias Advanced atrioventricular block Unstable angina Clinically significant pericardial disease Myocardial fibrosis Uncontrolled hypertension 4. Known hypersensitivity to any component of Neratinib, probiotics, placebo, or loperamide. 5. Prior participation in any clinical trial involving investigational drugs within 4 weeks prior to enrollment, or chronic use of medications that may induce constipation within 6 months. 6. Pregnant or lactating women, or those unwilling to use effective contraception during the study period. 7. Any medical, psychiatric, or social condition that, in the investigator's judgment, could compromise the safety of the participant, interfere with study participation, or confound the study results.
Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study
NCT06906081
Recruiting
Conditions Cardiovascular Autonomic Neuropathy, Typ...
Phase PHASE2
Enrollment 100
Locations 2 sites
Compensation Phase 2: Typically $500-$2,000
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • Kerendia (Finerenone, BAY94-8862)
  • Placebo

Primary Outcomes

  • Between-group (finerenone vs. placebo) difference in changes on the CART E/I ratio
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-05-02
Completion: 2028-01
Eligibility
Age: 40 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peter Rossing
Collaborators: Steno Diabetes Center Nordjylland, Aarhus University Hospital
Principal Investigators:
  • Peter Rossing, Professor, MD (PRINCIPAL_INVESTIGATOR) - Steno Diabetes Center Copenhagen
Contact Information
Study Contact:
Peter Rossing, Professor, MD
+4530913383
peter.rossing@regionh.dk
Christian Stevns Hansen, Ph.D, MD
+4561671618
christian.stevns.hansen@regionh.dk
Interventions
  • Kerendia (Finerenone, BAY94-8862)
  • Placebo
Study Locations (2 sites)
Steno Diabetes Center Northern Denmark, Gistrup, 9260 Denmark
Steno Diabetes Center Copenhagen, Herlev, 2730 Denmark
Eligibility Criteria
To be included in this study the participants must fulfill the following inclusion criteria. * Given informed consent * Type 2 diabetes defined by WHO criteria * Aged 40 ≥ at inclusion * Pathological E/I ratio (Mean value of three measures) Exclusion criteria Participants will be excluded in one or more of the following criteria are met. * No CAN (no abnormal CARTs) * Definite CAN (more than one abnormal CART) * HbA1C \>100 mmol/L * Treatment with potassium-sparing diuretics (amiloride) or MRAs e.g., spironolactone or eplerenone which cannot be discontinued 4 weeks prior to screening visit. The patient's primary physician, who is not involved in this study, will determine if discontinuation is possible. * Atrial fibrillation/flutter * Congestive heart failure (NYHA class 3-4) * History of cardiac arrhythmia * Severe forms of respiratory disease including asthma and COPD * Any nondiabetic cause of neuropathy * All female subjects of childbearing potential (WOCBP) must have a negative result of a highly sensitive urine HCG (pregnancy test) performed at screening. Subjects of childbearing potential must agree to use a highly effective form of contraception throughout the duration of the study (list of definition on WOCBP and accepted contraception in appendix A). * Severe hepatic impairment * Lactose intolerance * Breastfeeding * Nephropathy requiring dialysis * Beta-blocker-use * Hyperkalemia at screening visit (plasma potassium \>4.8 mmol/l) * eGFR \< 25 ml/min/1.73m2 * Potassium plasma \> 4.8 mmol/l (at randomization) * Treatment with strong CYP3A4-inhibitors (e.g. Itraconazol, ketoconazol, ritonavir, cobicistat, clarithromycin) which cannot be discontinued 4 weeks prior to screening visit * Treament with moderate to strong CYP3A4-induceres (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital, St John's Wort or efavirenz) which cannot be discontinued 4 weeks prior to screening visit * Have received chemotherapeutic treatment within last 12 months * Grapefruit consumption that cannot be discontinued during the study period * Inability to complete study protocol, assessed to investigator * Not able to read, write and/or understand Danish
Cognitive Function and EEG Brain Network Remodeling Among Users of Hearing Aids With ARHL
NCT06893432
Active, positions filled
Conditions Age-related Hearing Loss, Age-related Co...
Phase Not Applicable
Enrollment 60
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • hearing aids

Primary Outcomes

  • better-ear pure-tone averages (BEPTA)
  • binaural averaged pure-tone averages (BAPTA)
  • better-ear speech recognition thresholds (BESRT)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Active, positions filled
Start Date: 2024-12-01
Completion: 2025-03-31
Eligibility
Age: 50 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Principal Investigators:
  • Haidi Yang, Prof. (STUDY_DIRECTOR) - SunYatSunU2H
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • hearing aids
Study Locations (1 sites)
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510000, Guangzhou, Guangdong 510000 China
Eligibility Criteria
Inclusion Criteria: * Diagnosed with ARHL * Aged between 50 and 90 * Complete measuring data; including pure tone audiometry, speech audiometry, cognitive screening scales and resting-state electroencephalography * Right-handed * Regular daily use of hearing aid(s) for six-month period prior to the test date, or no hearing aid experience Exclusion Criteria: * Outer/middle ear abnormalities or any other central nervous system disorders
Comparison of Once-Weekly Trelagliptin Vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes
NCT06889909
Active, positions filled
Conditions Type 2 Diabetes Mellitus (T2DM)
Phase NA
Enrollment 102
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • Trelagliptin 100 mg
  • Vildagliptin 50 mg

Primary Outcomes

  • Percentage of Participants Achieving HbA1c <7%
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Active, positions filled
Start Date: 2024-12-15
Completion: 2025-06-15
Eligibility
Age: 30 Years
Sex: ALL
Volunteers: false
Enrollment: 102 (ACTUAL)
Sponsor & Investigators
Lead Sponsor: Lahore General Hospital
Principal Investigators:
  • Muhammad Irfan Jamil (PRINCIPAL_INVESTIGATOR) - Lahore General Hospital, Lahore
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Trelagliptin 100 mg
  • Vildagliptin 50 mg
Study Locations (1 sites)
Lahore General Hospital, Lahore, Lahore, Punjab Province 54000 Pakistan
Eligibility Criteria
Inclusion Criteria: * Adults aged 30-60 years. * Both male and female. * Diagnosed with type 2 diabetes mellitus. * HbA1c levels between 7.5% and 9.5% at screening. * Able to provide informed consent. Exclusion Criteria: * Type 1 diabetes mellitus or a history of ketoacidosis. * Use of insulin or any antidiabetic drugs other than metformin within 3 months prior to the start of the study. * Significant cardiovascular disease, including recent myocardial infarction (within the last 6 months), unstable angina, or uncontrolled hypertension. * Chronic kidney disease (stage 3 or worse) or hepatic or pancreatic dysfunction. * Pregnant or breastfeeding or planning to become pregnant during the study duration. * Participation in another clinical trial within 30 days prior to enrollment. * Known hypersensitivity to trelagliptin, vildagliptin, or any components of their formulations. * Any medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study. * Participants for whom blood sugar control by insulin preparations is desired (for example, participants with severe ketosis, diabetic coma or precoma, type 1 diabetes mellitus, severe infection, or serious trauma before or after surgery). * Participants with unstable proliferative diabetic retinopathy.
Clinical Efficacy, Safety, and Applicability of Home-based Bright Light Therapy in Outpatient Adolescents With Major Depressive Disorder
NCT06913309
Recruiting
Conditions Depressive Disorder, Major
Phase NA
Enrollment 168
Locations 3 sites
Compensation Compensation typically provided
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • Bright light therapy(High light intensity)
  • Bright light therapy(Low light intensity)
  • Dim red light placebo-controlled intervention

Primary Outcomes

  • Hamilton Depression Rating Scale-17(HAMD-17)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-17
Completion: 2026-06-30
Eligibility
Age: 13 Years
Sex: ALL
Volunteers: true
Enrollment: 168 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University Sixth Hospital
Contact Information
Study Contact:
Xiaozhen Lv
+8601062723705
lxz120300@163.com
Interventions
  • Bright light therapy(High light intensity)
  • Bright light therapy(Low light intensity)
  • Dim red light placebo-controlled intervention
Study Locations (3 sites)
Beijing Huilongguan Hospital, Beijing, Beijing Municipality 10000 China
Peking University Sixth Hospital, Beijing, Beijing Municipality 10000 China
Yan'an Third People's Hospital, Yanan, Shanxi China
Eligibility Criteria
The inclusion and exclusion criteria for MDD patients: 1. inclusion criteria * Meeting DSM-IV diagnostic criteria for a major depressive episode (first-episode or recurrent) , confirmed by two experienced, independent psychiatrists using the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-Kid); * Aged 13-17 years ; * Medication-naïve or on a stable pharmacological regimen for ≥1 week prior to enrollment; * Baseline Hamilton Depression Rating Scale-17 (HAMD-17) score ≥14; * Minimum of 5 years of formal education, with the ability to complete clinical assessments and comprehend study-related information; * Voluntary participation with written informed consent provided by both participants and their legal guardians. 2. exclusion criteria * Current or past diagnosis of psychiatric disorders other than anxiety or sleep disorders; * History of substance abuse or dependence history (including alcohol, nicotine, or illicit drugs); * Baseline Young Mania Rating Scale (YMRS) total score ≥6; * Received or planned to initiate non-pharmacological systemic interventions within 6 months prior to enrollment or within 1 month after enrollment, including but not limited to: structured psychotherapy (≥1 session/month for \>6 months), physical therapy (e.g., modified electroconvulsive therapy \[MECT\], repetitive transcranial magnetic stimulation \[rTMS\], transcranial direct current stimulation \[tDCS\], or deep brain stimulation \[DBS\]), or exercise therapy ; * Clinician-assessed suicide risk or a HAMD-17 item 3 score ≥3 at the baseline; * Presence of severe systemic or neurological conditions, such as diabetes, hypertension, renal failure, hepatic dysfunction, thyroid disorders, encephalitis, traumatic brain injury, or epilepsy; * Severe retinal pathologies (e.g., retinal detachment, optic atrophy, macular degeneration); or having high myopia (spherical equivalent ≤ -6.00 diopters); * Current use of photosensitizing agents or medications (e.g., chlorpromazine, hypericum extract); * Any other condition deemed inappropriate by the investigators(e.g., cases involving severe sleep phase delays that make morning therapy impossible, or unrecorded photosensitivity). The inclusion and exclusion criteria for Health controls 1. Inclusion criteria * Aged 13-17 years and right-handed; * Minimum of 5 years of formal education, with the ability to complete clinical assessments and comprehend study-related information; * Voluntary participation with written informed consent provided by both participants and their legal guardians. 2. Exclusion criteria * Current or lifetime diagnosis of any psychiatric disorders (e.g., schizophrenia, mood disorders, anxiety disorders) or history of substance/drug abuse or dependence; * First-degree family history of psychiatric disorders; * Presence of severe systemic or neurological disorders, such as diabetes, hypertension, renal failure, hepatic dysfunction, thyroid disorders, encephalitis, traumatic brain injury, or epilepsy; * Any other condition deemed inappropriate by the investigators.
Preoperative Magnetic Tracking in Breast Surgery in France: French Medical-economic Study.
NCT06906601
Recruiting
Conditions Breast Cancer, Medico-economic Impact, B...
Phase Not Applicable
Enrollment 772
Locations 7 sites
Compensation Compensation varies
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • magnetic clip localization
  • metallic wire localization.
  • Breast cancer surgery

Primary Outcomes

  • Comparison of the average total cost of patient care with magnetic clip localization versus the use of a hookwire, up to 6 months post-surgery
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-04-15
Completion: 2027-10-15
Eligibility
Age: 18 Years
Sex: FEMALE
Volunteers: false
Enrollment: 772 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Leon Berard
Contact Information
Study Contact:
Severine Metzger
+33 (0)4 78 78 27 86
severine.metzger@lyon.unicancer.fr
Marie Osdoit, Dr
Marie.OSDOIT@lyon.unicancer.fr
Interventions
  • magnetic clip localization
  • metallic wire localization.
  • Breast cancer surgery
Study Locations (7 sites)
Hospices Civils de Lyon Hopital de la Croix rousse, Lyon, 69004 France
Centre Léon Bérard, Lyon, 69008 France
Institut de Cancérologie de Lorraine (ICL), Nancy, 54519 France
Hôpital Nord -Ouest Val d'Oise (NOVO), Pontoise, 95300 France
Institut GODINOT, Reims, 51726 France
Centre Eugène Marquis, Rennes, 35042 France
Institut Gustave Roussy, Villejuif, 94805 France
Eligibility Criteria
Inclusion Criteria: * I1. Female aged ≥ 18 years; * I2. Patient presenting with a unifocal and unilateral lesion of invasive carcinoma or in situ; * I3. Indication for first breast-conserving treatment with the need for preoperative localization of the lesion, regardless of the associated lymph node procedure; * I4. Patient affiliated with a health insurance system; * I5. Non-opposition to the study. Exclusion Criteria: * E.1. Psychological, family, or sociological condition that may potentially compromise adherence to the treatment protocol and follow-up; * E.2. Bilateral surgery required; * E.3. Patient with metastatic breast cancer; * E.4. Multifocal or benign lesions; * E.5. Pregnant or breastfeeding patient; * E.6. Need for neoadjuvant treatment; * E.8. Patient under guardianship, curatorship, or deprived of liberty.
Personalized Care for Prenatal Stress Reduction & Prevention of Preterm Birth (PTB) Disparities
NCT06915428
Not yet recruiting
Conditions Preterm Birth Complication, Preterm Birt...
Phase NA
Enrollment 1228
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • Care coordination
  • Electronic massage
  • support gift #1
  • Support gift #2
  • Support gift #3

Primary Outcomes

  • Self-reported Perceived Stress Scores
  • Self-reported resilience scores
  • Maternal blood-based stress-related gene transcript levels
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2026-08-01
Completion: 2029-01
Eligibility
Age: 18 Years
Sex: FEMALE
Volunteers: false
Enrollment: 1228 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of North Carolina, Chapel Hill
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Principal Investigators:
  • Tracy Manuck, MD (PRINCIPAL_INVESTIGATOR) - University of North Carolina, Chapel Hill
Contact Information
Study Contact:
Tracy A Manuck, MD, MSCI
8015998164
tmanuck@med.unc.edu
Amber Ivins
9199661601
amber_ivins@med.unc.edu
Interventions
  • Care coordination
  • Electronic massage
  • support gift #1
  • Support gift #2
  • Support gift #3
Study Locations (1 sites)
University of North Carolina School of Medicine - Chapel Hill, Chapel Hill, North Carolina 27599 United States
Eligibility Criteria
Inclusion Criteria: 1. Viable, singleton pregnancy, 8+0 to 19+6 weeks, dated by last menstrual period ± ultrasound using standard obstetric criteria per American College of Obstetricians and Gynecologists. Gestational age at first ultrasound by last menstrual period (LMP) / Ultrasound method / Measurement agreement with LMP required • Up to 8 weeks 6 days / crown rump length / ± 5 days * 9 weeks 0 days to 13 weeks 6 days / crown rump length / ± 7 days * 14 weeks 0 days to 15 weeks 6 days / standard fetal biometry / ± 7 days * 16 weeks 0 days to 19 weeks 6 days / standard fetal biometry / ± 10 days * Gestational dating / fetal viability must be confirmed by ultrasound prior to enrollment / randomization. * Ultrasound report must include documentation of normal fetal heart rate of ≥ 120 beats per minute, or subsequent medical record documentation of auscultation of fetal heart rate ≥ 120 beats per minute. * Viability must be confirmed / re-confirmed within 7 days of randomization. If initial consent occurs early in pregnancy and V1/randomization occur later, viability must be reconfirmed to ensure ongoing eligibility prior to initiating V1 activities (including surveys) and proceeding with randomization. 2. No signs or symptoms of, or clinical diagnosis of, evolving miscarriage, active preterm labor, preterm prelabor rupture of membranes at the time of enrollment. * Cervical dilation at the time of enrollment is an exclusion criterion. However, cervical evaluation and digital cervical exam is not required prior to enrollment. (3a) High a priori risk for medically indicated preterm birth - must meet at least one of the following 3 criteria (maternal medical history, prior pregnancy history, or moderate risk factor history) * miPTB criteria #1: Maternal Medical History - any one of the following: o Known chronic hypertension requiring medications in the 3 months prior to conception or prior to 22 weeks gestation. o At least 2 blood pressure readings 6 hours apart, \<20 weeks gestation, with systolic ≥ 130 mmHg or diastolic ≥ 80 mmHg \*regardless of need for medication or formal diagnosis of hypertension in chart\* o Pre-gestational diabetes mellitus. * Diabetes diagnosed \<20 weeks gestation. * Maternal chronic or sub-acute renal disease, including chronic kidney failure, chronic renal insufficiency, glomerulonephritis, lupus nephritis, defined as any: \*biopsy proven chronic renal disease history; and/or \*serum creatinine ≥ 1.1 mg/dL at any time during pregnancy prior to enrollment, in the absence of other identifiable transient factors per clinician's assessment (e.g., extreme dehydration, cystitis, pyelonephritis); and/or \*chronic proteinuria, defined as baseline urine protein:creatinine ratio ≥ 0.30 mg/dL or 24 hour total urine protein ≥ 300 mg in the absence of other identifiable transient factors per clinician's assessment (e.g., extreme dehydration, cystitis, pyelonephritis) \*Systemic Lupus Erythematosus * Antiphospholipid Antibody Syndrome * miPTB criteria #2: Prior pregnancy history - any ONE of the following: o Previous pregnancy complicated by preeclampsia or hypertensive disorders of pregnancy at any gestational age, in a singleton gestation; the fetus must not have had major structural anomalies or aneuploidy. o Previous history of stillbirth ≥ 16+0 weeks in a singleton gestation; the fetus must not have had major structural anomalies or aneuploidy. The stillbirth etiology must not have been attributed to physical trauma (e.g., domestic violence, motor vehicle accident) or illicit drug use (e.g., cocaine use leading to abruption and stillbirth). * miPTB criteria #3: Any two or more of the following moderate risk factors: o Nulliparity, defined as no prior pregnancy to reach at least 20 weeks gestation note that this is the traditional / classic definition of 'nulliparous' and that there is overlap between nulliparity as defined this way and 'preterm birth' due to cervical insufficiency, which allows for deliveries in the 16-19 week gestational age range to be considered as 'preterm births' o Obesity: current or pre-pregnancy body mass index ≥30 kg/m\^2 o Family history: first degree relative with a history of preeclampsia o Advanced maternal age: maternal age ≥ 35 years at estimated date of confinement o Prior adverse obstetric history - one or more of the following: \- history of low birth weight or small for gestational age baby in a singleton gestation, defined as weight \<10% for gestational age and fetal sex; the fetus must not have had major structural anomalies or aneuploidy. \- history of adverse pregnancy outcome in a singleton gestation; the fetus must not have had major structural anomalies or aneuploidy. o Long interpregnancy interval: ≥ 10 year (3650 day) pregnancy interval, defined as the time (in days) between the date of delivery of the last pregnancy to reach ≥ 20 weeks gestation and the first day of the last menstrual period for the current pregnancy. o Black or African-American race (as a proxy for underlying racism) - self-reported. Participants who self-identify as being of more than one racial group will be considered to be of Black race for the purposes of this criterion if one of the racial groups is Black or African-American. * Low socioeconomic status, defined as one or more of the following: housing or food insecurity noted in chart within the last year, self-pay or Medicaid insurance, less than high school education and/or (3b) High a priori risk for spontaneous preterm birth - must meet at least one of the following 2 criteria (prior pregnancy history or current pregnancy course) * sPTB criteria #1: Prior pregnancy history * EITHER a history of a delivery of a singleton, non-anomalous baby between 16+0 and 34+6 weeks gestation or delivery of a twin, non-anomalous pregnancy between 160 /7and 276 /7 weeks gestation due to spontaneous preterm labor, preterm premature rupture of membranes, cervical insufficiency, or placental abruption - Chart documentation of prior preterm birth, the gestational age of the prior preterm birth (referred to as the 'qualifying delivery') should be determined. If the gestational age at delivery is obtained directly from the medical record and more than one gestational age appears, the greater of the two will be used assuming that neither is the 'source document' (i.e. an ultrasound report with a due date, a c-section report, a delivery note, etc). Use the following table as a validation of the previous delivery. For example, if the infant was male and weighed more than 2763 grams (6 pounds, 1.5 ounces) then the patient would be ineligible based on history of a preterm birth criteria. This table should only be used to determine whether the qualifying delivery is most likely to be preterm less than 35 weeks gestation when the gestational age CANNOT be verified/calculated by review of the medical records or is not available in the medical records. Gestational age 90th percentile - boys 90th percentile - girls 33 weeks \> 2488g 5 lbs 7.8 oz \> 2116g 4 lbs 10.6 oz 34 weeks \> 2763g 6 lbs 1.5 oz \> 2379g 5 lbs 3.9 oz 35 weeks \> 3084g 6 lbs 12.8 oz \> 2661g 5 lbs 13.9 oz * Documented history of a prior pregnancy complicated by asymptomatic cervical shortening \<25mm between 16+0 and 23+6 weeks gestation or cervical dilation ≥ 0.5cm requiring cervical cerclage placement prior to 24+0 weeks gestation, even if delivery ultimately occurred ≥ 35 weeks gestation or at term. • sPTB criteria #2: Current pregnancy course * Asymptomatic cervical shortening \<25mm in the current pregnancy, diagnosed by transvaginal ultrasound that is performed ≥14+0 weeks gestation, per Registered Diagnostic Medical Sonographer(RDMS) certified Sonographer or physician with transvaginal ultrasound training program (or similar) qualific
Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab
NCT06881940
Not yet recruiting
Conditions Cancer Therapy-Related Cardiac Dysfuncti...
Phase NA
Enrollment 284
Locations 2 sites
Compensation Compensation typically provided
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • Rehabilitation Program
  • No Rehabilitation Program

Primary Outcomes

  • Incidence of cardiac dysfunction or heart failure as a manifestation of cardiovascular toxicity in the intervention group and control group
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2025-04-01
Completion: 2029-12-01
Eligibility
Age: 18 Years
Sex: FEMALE
Volunteers: false
Enrollment: 284 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez
Collaborators: Instituto Nacional de Cancerologia de Mexico
Contact Information
Study Contact:
Nilda G. Espinola-Zavaleta, M.D., Ph.D
+525555732911
niesza2001@hotmail.com
Neftali Eduardo Antonio-Villa, M.D., Ph.D
+525555732911
eduardo.villa@cardiologia.org.mx
Interventions
  • Rehabilitation Program
  • No Rehabilitation Program
Study Locations (2 sites)
Instituto Nacional de Cancerología (INCAN), Mexico City, Mexico City 14080 Mexico
National Institute of Cancerology (INCAN), Mexico City, Mexico City 14080 Mexico
Eligibility Criteria
Inclusion Criteria: * Women aged between 18 and 70 years will be considered eligible. * Active residents of any municipality within Mexico City and the surrounding metropolitan area will qualify, conditioned that their maximum travel time from their residence to our recruitment center does not exceed three hours using private or public transportation. This criterion is established to ensure adherence to the protocol and availability for participation in the required interventions and assessments throughout the study. * Patients diagnosed with early-stage or locally advanced breast cancer (stages I, II, or III, according to the TNM classification-Tumor, Node, Metastasis) who will undergo treatment with anthracyclines and/or adjuvant/neoadjuvant anti-HER2 therapy will be included. Participants must be scheduled to receive pharmacological treatment, ensuring that the study focuses on a population undergoing specific therapies for breast cancer management. * Candidates must have the capacity, availability, and willingness to participate in an aerobic and resistance exercise program. Participants are required to possess both the physical ability and the willingness to actively engage in a structured exercise program, which includes aerobic and resistance activities essential to the study's objectives. * Patients will provide informed written consent to participate in the study. To uphold ethical research principles and ensure the protection of participants' rights, all patients must voluntarily give their informed consent after receiving comprehensive information regarding the study's objectives, procedures, benefits, and potential risks. Exclusion Criteria: * Metastatic disease: Individuals with medical or imaging evidence of metastasis to any peripheral organ. * Cardiovascular disease: Patients with a self-reported history of cardiovascular conditions, such as heart failure or uncontrolled hypertension, that may limit their ability to safely engage in physical activity. Additionally, those with peripheral arterial disease or valvular heart disease will not be eligible. * Ischemic heart disease: Patients with a history of ischemic heart disease. * Neurological disorders: Individuals with self-reported neurological diseases that significantly impair coordination, balance, or motor control, such as advanced Parkinson's disease, late-stage multiple sclerosis, or paralysis, making physical activity unsafe. * Musculoskeletal conditions: Patients with self-reported musculoskeletal injuries or disorders that hinder physical activity, including fractures within the last five years, moderate to severe sprains, tendinitis, or severe arthritis. * Uncontrolled systemic comorbidities: Individuals with decompensated systemic conditions, including heart failure, chronic kidney disease, or poorly controlled diabetes, will be excluded. * Severe respiratory diseases: Patients with severe respiratory conditions that prevent physical exercise participation. * Physical limitations: Individuals with mobility impairments or conditions requiring constant assistance for basic physical activities, such as those using assistive devices (e.g., wheelchairs, walkers) or with limb amputations, will not be eligible for participation. * Severe psychiatric disorders: Patients with uncontrolled psychiatric conditions, including schizophrenia, severe bipolar disorder, or major depressive disorder, that may interfere with their ability to actively participate in a supervised exercise program. Elimination Criteria: * Voluntary withdrawal from the protocol. * Development of severe cardiotoxicity requiring pharmacological treatment. * Adverse reactions to chemotherapeutic agents. * Disease progression according to the TNM classification during treatment. * Failure to complete at least 80% of the prescribed adjuvant or neoadjuvant oncological treatment. * Occurrence of adverse events during the study, such as falls or injuries. * Death during the study period. * Any accident related to the exercise protocol, including falls, sprains, or fractures.
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
NCT06902311
Recruiting
Conditions Breast Cancer, Early-stage Breast Cancer...
Phase PHASE2
Enrollment 90
Locations 1 sites
Compensation Phase 2: Typically $500-$2,000
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • Breast Radiotherapy

Primary Outcomes

  • Rate of any moderate-marked adverse effects
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-02-19
Completion: 2028-02
Eligibility
Age: 50 Years
Sex: FEMALE
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UNC Lineberger Comprehensive Cancer Center
Principal Investigators:
  • Dana Casey, MD (PRINCIPAL_INVESTIGATOR) - UNC Lineberger Comprehensive Cancer Center
Contact Information
Study Contact:
Jessica Buddenbaum
919-966-4432
jessica_buddenbaum@med.unc.edu
Cory Grreenwood
919-445-4929
cory_greenwood@med.unc.edu
Interventions
  • Breast Radiotherapy
Study Locations (1 sites)
University of North Carolina, Chapel Hill, North Carolina 27599 United States
Eligibility Criteria
In order to participate in this study a subject must meet all of the eligibility criteria outlined below. Inclusion Criteria: * Willing and able to provide written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information. * Women ≥ 50 years of age with confirmed de novo invasive carcinoma of breast or ductal carcinoma in situ. * Subjects with completed breast-conserving surgery (BCS) with or without sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND). * Subjects planned to receive either SOC whole breast 3D conformal radiation therapy (3D CRT) or SOC whole breast intensity modulated radiation therapy (IMRT) with standard dose tumor bed boost. * Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial, per the discretion of the treating radiation oncologist. * Enrollment in another clinical trial is allowed if there is no interference with interventions on this trial per discretion of the Principal Investigator. Exclusion Criteria: * Receipt of concurrent breast reduction involving tissue rearrangement in the lumpectomy cavity (so that boost cannot be accurately targeted). * Synchronous bilateral breast cancer requiring bilateral radiation therapy. * Clinical or imaging evidence of distant metastases. * Prior ipsilateral breast or thoracic radiation. * Autoimmune conditions * Collagen Vascular Disease (such as systemic lupus erythematosus, scleroderma, dermatomyositis, among others) * Patients with pT4 tumors. * Patients recommended to receive regional nodal irradiation with associated radiation risks
The Glaucoma and Retinopathy Screening Study
NCT06882356
Recruiting
Conditions Glaucoma
Phase NA
Enrollment 2000
Locations 5 sites
Compensation Compensation typically provided
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • AI-based glaucoma screening
  • IOP measurement
  • Virtual Reality Visual Field Testing

Primary Outcomes

  • Glaucoma detection
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-16
Completion: 2030-09
Eligibility
Age: 40 Years
Sex: ALL
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts Eye and Ear Infirmary
Collaborators: Centers for Disease Control and Prevention
Principal Investigators:
  • David S Friedman, MD, PhD, MPH (PRINCIPAL_INVESTIGATOR) - Massachusetts Eye and Ear
Contact Information
Study Contact:
David S Friedman, MD, PhD, MPH
617-573-3094
grass@mgb.org
Interventions
  • AI-based glaucoma screening
  • IOP measurement
  • Virtual Reality Visual Field Testing
Study Locations (5 sites)
Brigham and Women's Primary Care Associates of Longwood, Boston, Massachusetts 02115 United States
MGH Chelsea HealthCare Center, Chelsea, Massachusetts 02150 United States
NSPG Lynn, Lynn, Massachusetts 01904 United States
NSPG Salem, Salem, Massachusetts 01970 United States
NSPG Saugus, Saugus, Massachusetts 01906 United States
Eligibility Criteria
* Individuals with diabetes undergoing AI-based screening for diabetic retinopathy using the LumineticsCore (Digital Diagnostics) system for clinical care at primary care centers. * Individuals who are able and willing to provide informed consent for participation in the study.
Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression
NCT06898606
Recruiting
Conditions Depressive Disorder
Phase PHASE1, PHASE2
Enrollment 24
Locations 1 sites
Compensation Phase 1: Typically $1,000-$5,000
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • Psilocybin and Psilocyn
  • Placebo
  • Psychotherapy-assisted session
  • Fluoxetine

Primary Outcomes

  • Montgomery-Åsberg Depression Rating Scale (MADRS)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2024-09-05
Completion: 2026-11-20
Eligibility
Age: 25 Years
Sex: ALL
Volunteers: true
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Federal University of Latin American Integration
Principal Investigators:
  • Francisney P Nascimento, 1 (STUDY_DIRECTOR) - Federal University of Latin American Integration
Contact Information
Study Contact:
Francisney P Nascimento, 1
+55 45 99933-3479
ensaios.clinicos.lcp@unila.edu.br
Interventions
  • Psilocybin and Psilocyn
  • Placebo
  • Psychotherapy-assisted session
  • Fluoxetine
Study Locations (1 sites)
Federal University of Latin American Integration, Foz do Iguaçu, Paraná 85870-650 Brazil
Eligibility Criteria
Inclusion Criteria Age: ≥25 and \<65 years. Diagnosis: Current Major Depressive Disorder (MDD), moderate to severe, per DSM-5-TR, confirmed with SCID-5. Baseline severity: MADRS ≥20 at baseline (reassessed at the pre-dose visit to confirm ongoing eligibility). Partial Response in the current episode (PRD): ≥1 adequate antidepressant trial in this episode (therapeutic dose for ≥6-12 weeks, adherence ≥80%) with \<50% symptom reduction or clinically significant residual symptoms. Clinical stability and ability to provide informed consent; willingness to comply with all study procedures (preparation, dosing session, integration, and follow-ups). Contraception: For participants with reproductive potential, negative pregnancy test and agreement to use effective contraception during the study. Exclusion Criteria Psychiatric disorders: Bipolar I/II disorder, any psychotic disorder, or current MDD with psychotic features; first-degree family history of psychotic or bipolar disorder. Suicide risk: Acute suicidal risk, e.g., active suicidal ideation with intent or plan, recent attempt, or clinical judgment requiring urgent intervention. Interacting medications: Current use of serotonergic antidepressants (SSRI/SNRI/MAOI, clomipramine) or other pro-serotonergic agents (e.g., triptans, linezolid, lithium, tramadol, dextromethorphan) that cannot be discontinued per protocol-defined washout. Other psychotropics: Unstable doses of antipsychotics, mood stabilizers, or long-acting benzodiazepines within the last 2 weeks; need for medications that would compromise blinding on the dosing day. Psychotherapy changes: Initiation or major change in psychotherapy within 2 weeks prior to baseline (to preserve clinical stability). Medical conditions: Clinically significant or unstable medical illness (cardiovascular, neurological, hepatic, renal), prolonged QTc, known hypersensitivity/contraindication to fluoxetine or study materials. Pregnancy or breastfeeding. Substance use: Current substance use disorder (excluding nicotine/caffeine) within the past 3 months; non-medical cannabis use that cannot meet the pre-dose abstinence window (e.g., ≥72 h). Any condition that, in the investigator's opinion, would make participation unsafe or interfere with the assessments. Washout note (to include in Procedures/Eligibility): SSRIs/SNRIs: 7 days or ≥5 half-lives; prior fluoxetine: ≥6 weeks; MAOIs: ≥14 days before randomization/dosing. Participants must be willing and able to follow the washout schedule.
Pulmonary Deposition of Ultrasound Rock Salt Aerosol Inhalation Therapy
NCT06891274
Not yet recruiting
Conditions COPD, Asthma Bronchiale, Chronic Bronchi...
Phase NA
Enrollment 26
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • USN before SVN
  • SVN before USN

Primary Outcomes

  • In Vitro Model Pulmonary Deposition Rate
  • Pulmonary Drug Deposition Rate
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2025-03-31
Completion: 2026-03-31
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 26 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jingen Xia
Principal Investigators:
  • Jingen Xia, M.D (STUDY_DIRECTOR) - China-Japan Friendship Hospital
Contact Information
Study Contact:
Jingen Xia, M.D
+8613466396561
xiajingen_00632@163.com
Interventions
  • USN before SVN
  • SVN before USN
Study Locations (1 sites)
China-Japan Friendship Hospital, Beijing, China
Eligibility Criteria
Inclusion Criteria: Healthy volunteers; Patients with chronic airway disease requiring nebulization therapy. Exclusion Criteria: Those aged \< 18 years; Refusing to participate in the study; Patients requiring invasive ventilator assisted breathing; Patients with artificial airways. Patients with chronic liver and kidney function injury. Allergic to radioactive elements.
Experience of Biologic Treatments for Severe Asthma: a Survey
NCT06903780
Recruiting
Conditions Severe Asthma
Phase Not Applicable
Enrollment 400
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-07-28
Click to view full details
Study Details Design, interventions, and primary outcomes

Interventions / Regimen

  • Survey using a questionnaire.

Primary Outcomes

  • Severe asthma biologic experience survey
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-01
Completion: 2025-12-31
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Royal Devon and Exeter NHS Foundation Trust
Collaborators: University of Plymouth, University Hospital Plymouth NHS Trust, Newcastle-upon-Tyne Hospitals NHS Trust, University Hospital Birmingham, Barts & The London NHS Trust, Guy's and St Thomas' NHS Foundation Trust
Principal Investigators:
  • Matthew Masoli, MD (PRINCIPAL_INVESTIGATOR) - Royal Devon and Exeter NHS Foundation Trust
Contact Information
Study Contact:
Joseph Lanario, PhD
+44 01752 764403
joseph.lanario@plymouth.ac.uk
Alison Kerridge, PhD
+44 01392 403055
alison.kerridge@nhs.net
Interventions
  • Survey using a questionnaire.
Study Locations (1 sites)
Royal Devon University Healthcare NHS Foundation Trust, Exeter, Devon EX2 5DW United Kingdom
Eligibility Criteria
Inclusion Criteria: Receiving a biologic treatment for at least 6 months. • But has not been on the treatment for longer than 18 months. Note: In clinical practice, a 12-month trial of biologic treatments is needed before a decision to stop/switch treatment is made. Therefore, our inclusion criteria will capture people who are non-responders to biologic treatments. Exclusion Criteria: * Patients will be excluded if they are unwilling/unable to provide consent to use their data. * Patients who have switched biologics will also be excluded. * In the opinion of the physician responsible for the care of the patient, the patient has a condition, other than asthma which is significantly contributing to their respiratory symptoms, e.g. lung cancer, heart failure or severe COPD.